Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 5/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644647 | 1.00 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL16237539 | 0.98 | HDAC3 (0.41) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL27589267 | 0.86 | SLC7A5 (0.39) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL7713974 | 0.81 | HDAC3 (0.44) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL25495577 | 0.81 | CTSK (0.38) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL18575988 | 0.81 | CTSK (0.38) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL27176972 | 0.79 | HDAC3 (0.45) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL31301962 | 0.79 | CYP2D6 (0.44) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL2331892 | 0.79 | CYP2D6 (0.44) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL7347959 | 0.78 | CYP2D6 (0.45) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724068-A2 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724061-A2 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12551582-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2025226524-A1 | GRANZYME B PET IMAGING AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4561629-A2 | THERANOSTIC COMPOUNDS TARGETING GRANZYME B | Cytosite Biopharma Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250032650-A1 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2024254417-A2 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024254479-A2 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240390530-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2024-11-28 | — | — | US | disclosed |
| EP-4444292-A1 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-5874424-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-02-23 | — | — | US | disclosed |
| US-5847135-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998024805-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5716929-A | THERAPY FOR INFLAMMATION, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| CN-1159196-A | Inhibitors of interleukin-1'beta' converting enzyme | VERTEX PHARMA (US) | 1997-09-10 | — | — | CN | disclosed |
| US-5656627-A | USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390530-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | HDAC3 3992/4885HDAC1 4163/4885HDAC2 4363/4885 |
| US-20250032650-A1 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | GZMB, PRF1, CTSB | HDAC3 2733/4885HDAC1 2858/4885HDAC2 3484/4885 |
| US-12551582-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | HDAC3 3282/4885HDAC1 3847/4885HDAC2 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.